The LIT - Leibniz Institute for Immunotherapy (foundation under civil law) (https://lit.eu) – is a biomedical research center focusing on translational immunology in the fields of cancer immunotherapy, transplant rejection and autoimmunity. The objective of the LIT is to develop innovative and efficient cellular immune therapeutics in these areas. Our own GMP laboratories and close networking with University and University Hospital offer excellent opportunities for clinical translation of novel immune cell products.

The Clinical Translation Group “T Cell Fitness” at the LIT is recruiting a

PhD position (m/f/d) – RS-2026-1



Starting January 2027. The position is initially limited to three years, with the possibility of extension.

 

About the group:

The T Cell Fitness group at the Leibniz Institute for Immunotherapy (LIT) in Regensburg develops innovative platform technologies to improve T-cell-based immunotherapies for solid tumors, with a strong focus on clinical translation.

By combining T-cell engineering, molecular biology, functional assays, and preclinical tumor models, we aim to enhance T-cell fitness, persistence, and antitumor activity within the challenging tumor microenvironment. Our goal is to overcome current limitations of adoptive T-cell therapies and advance promising strategies toward clinical application.

Your Role:

You will develop engineered T-cell therapies to enhance their fitness and antitumor activity in solid tumors. Your responsibilities will include:

  • Designing, generating, and validating genetically modified T-cell constructs
  • Cultivation, expansion, and genetic modification of T cells
  • Performing viral transduction and establishing stable cell lines
  • Conducting in vitro functional assays, including cytotoxicity and repeated tumor rechallenge assays 
  • Characterizing engineered T cells using flow cytometry, ELISA, and other cell-based assays
  • Planning and performing preclinical in vivo studies 
  • Analyzing experimental data to evaluate T-cell fitness, persistence, and antitumor efficacy
  • Contributing to experimental protocols, SOPs, and translational research documentation
  • Presenting research findings and contributing to scientific publications

Your profile:

  • Master's degree in biology, molecular medicine or a related field

  • At least two years of hands-on experience in preclinical solid tumor models including both murine syngeneic and xenograft tumor models

  • Approved laboratory animal science training covering both basic experimental procedures and surgical techniques (e.g. relevant FELASA-aligned qualifications)

  • Experience in the cultivation and genetic modification of both primary human and murine T cells

  • Practical experience in viral transduction and the generation of stable genetically modified cell lines

  • Experience in establishing and performing in vitro cytotoxicity assays, including longitudinal killing assays and repeated tumor rechallenge experiments using Incucyte® and xCELLigence® devices

  • Experience in the identity proof of engineered immune cells using multiparameter flow cytometry, ELISA and qPCR

  • Experience in the planning, execution, and analysis of in vivo tumor experiments, including tumor monitoring, tissue collection, and downstream immunological analyses

  • Strong interest in T-cell engineering, immune cell fitness, and the development of next-generation platform technologies for solid tumors

  • Familiarity with GCP and GMP principles, including documented training or certification in the relevant regulatory standards

  • Excellent oral and written communication skills in English

  • Ability to work independently, combined with a collaborative and solution-oriented mindset

We offer:

  • An international cutting-edge research environment that offers exciting and diverse opportunities

  • Perspectives for further scientific qualification

  • Flexible working hours

  • Flat hierarchies and short decision-making processes

  • A highly motivated and cooperative team

  • Possibility to enroll in the RIGeL graduate school

  • Company pension scheme (VBL)

  • Annual special payment

  • Capital-forming benefits

  • Job ticket and more

The remuneration is based on TV-L (E13, 65%). 

The LIT places particular emphasis on promoting a healthy work-life balance.

Disabled applicants (m/f/d) with equal qualifications will receive preferential treatment within the recruitment procedure. Please refer to your disability status already in your application.

Please note that expenses that may arise in the context of an eventual job interview cannot be reimbursed. 

For more information, please contact Assoc. Prof. Dr. Dr. Roland Schelker (roland.schelker@lit.eu). 

A logo of a company Description automatically generatedWe are looking forward to receiving your detailed application. Please apply via our Online - Application Portal quoting the reference RS-2026-1. 

The application deadline is 02.12.2026.